ACASTI PHARMA INC (ACST)
CA00430K8656 - Common Stock
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA)Patient...
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
Accepted for Presentation at the 2024 International Stroke Conference...
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing...
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led...
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
Virtual Webinar to Take Place October 11, 2023 at 2:00pm ET...
Acasti Pharma director discloses purchase of 676,371 shares (NASDAQ:ACST)
Acasti Pharma's director recently purchased over $1.2 million worth of company shares, indicating confidence in its potential growth.
Acasti announces $7.5M private placement equity funding (NASDAQ:ACST)
Acasti Pharma closes private placement, raising $7.5M to fund clinical trial expenses for GTX-104 in phase 3 trial.
Acasti Announces $7.5 Million Private Placement Equity Financing
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing...
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
New leadership team singularly focused on executing GTX-104 strategyAnnounced alignment with the U.S. Food and Drug Administration (FDA) for Pivotal...
Acasti Pharma announces 1-for-6 reverse stock split (NASDAQ:ACST)
Canadian biopharma company Acasti Pharma (ACST) said on Friday that it will effect a 1-for-6 reverse stock split to increase the company's per share market price to regain compliance with..
Acasti Pharma Announces 1-for-6 Reverse Stock Split
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel injectable...
Acasti Pharma Reports Fiscal Year 2023 Operational Results
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday!
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, specialty pharma company advancing drug candidates for rare and...
Acasti Pharma Inc. Announces the Resignation of a Director
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clinical stage drug...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
The biggest pre-market stock movers are making waves on Wednesday with huge gainers and losers worth watching this morning!
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical...
Acasti Pharma Recognizes Rare Disease Day
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical...
Acasti Pharma Reports Third Quarter 2023 Operational Results
Acasti Pharma Reports Third Quarter 2023 Operational Results
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”)...
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage,...
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage,...
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage...
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage,...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage,...